skip to Main Content

Oxford University adopts OL

UPPSALA, Sweden, May 09, 2022 (GLOBE NEWSWIRE) — Olink Holding AB (publ) (OLK) today announced that Oxford Genomics at the University of Oxford is adopting Olink technology and becoming the first Olink-certified laboratory in the UK. Partnership will enable new techniques to unravel disease mechanisms using Olink® Explore the platform.

Oxford Genomics is centered within the Wellcome Center of Human Genetics which was formed during the founding years of the Human Genome Project; they have been producing cutting-edge research for over two decades. As we enter an era of multi-omics analysis to truly understand the link between disease and phenotype, proteomics is an essential tool to complement their other advanced technologies.

With the recent creation of the Oxford-GSK Institute, Olink® Explore will be used to build a multiomics approach to map the molecular mechanisms of complex diseases such as Parkinson’s disease and Alzheimer’s disease. Machine learning expertise and bioinformatics at Oxford’s Big Data Institute will be able to mine these datasets to identify new targets and identify signatures to stratify patients.

“Using the Olink platform, we aim to discover biomarkers and early disease signatures in common diseases, as they would provide clues to drug targets and readouts that we can use to test potential therapeutic candidates,” said Professor John Todd, director of the Wellcome Center for Human Genetics and co-director of the Oxford GSK Institute. “We are trying to make the drug development process more precise by understanding patient heterogeneity instead of one drug for all.”

The new Olink® The Explore 3072 platform provides access to an extensive library of carefully selected and validated assays to provide detailed proteomics data to improve understanding of human health. Olink’s market-leading proteomics solution measures up to 3,000 proteins per sample using Proximity Extension Assay (PEA) technology combined with Next Generation Sequencing (NGS) readout, providing a highly multiplexed method accurate and reproducible with exceptional specificity.

“We are extremely proud to lay the foundations for a lasting and successful partnership with such a prestigious institution as the University of Oxford, using our technology as the first Olink certified laboratory in the UK. This partnership demonstrates the importance of academic partners in the implementation of new technologies. This will further democratize the use of the Olink platform in line with our mission to accelerate proteomics with the scientific community,” said Jon Heimer, CEO, Olink Proteomics. “The goal is to create a better understanding of the origin of diseases, provide earlier and more accurate diagnoses with individualized treatment, and enable more efficient and safer drug development.”

Contact Investor
Jan Medina, CFA
Vice President Investor Relations and Capital Markets
Mobile: +1 617 802 4157
[email protected]

Media Contact
Andrea Prander
Corporate Communications Manager
Mobile: +46 768 775 275
[email protected]

About Olink
Olink Holding AB (OLK) is a company dedicated to accelerating proteomics in collaboration with the scientific community, in multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services that are deployed across leading pharmaceutical companies and leading clinical and academic institutions to deepen understanding of human biology in real time and drive 21st century healthcare through science. actionable and impactful. The company was founded in 2016 and is well established in Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.

About the Wellcome Center for Human Genetics
The Wellcome Center for Human Genetics (WCHG) is a research institute of the Nuffield Department of Medicine, University of Oxford, funded by the University, Wellcome and many other sponsors. It is based in purpose-built laboratories at the University of Oxford’s Biomedical Research Campus in Headington, one of the largest concentrations of biomedical expertise in the world. Here, our researchers can work closely with colleagues from all academic departments, including but not limited to the Department of Psychiatry, Division of Cardiovascular Medicine, and the Big Data Institute.

With over 400 active researchers and approximately 70 staff in administrative and support roles, the Center is an international leader in genetics, genomics and structural biology. The WCHG collaborates with research teams around the world on a number of large-scale studies in these areas. WCHG researchers spend almost £20 million a year on competitively won grants and publish around 300 primary papers a year.

About Oxford University
The University of Oxford has been ranked number 1 in the Times Higher Education World University Rankings for the sixth consecutive year and number 2 in the QS World Rankings 2022. At the heart of this success are the two pillars of our groundbreaking research and innovation and our distinctive educational offering.

Oxford is world renowned for its excellence in research and teaching and is home to some of the most talented people in the world. Our work helps the lives of millions of people by solving real-world problems through an extensive network of partnerships and collaborations. The breadth and interdisciplinary nature of our research and our personalized approach to teaching spark imaginative and inventive ideas and solutions.

Through its research commercialization arm, Oxford University Innovation, Oxford is the largest applicant for university patents in the UK and ranks first in the UK for university spin-off companies, having created more than 200 new companies since 1988. More than a third of these companies have been created. over the past three years. The university is a catalyst for prosperity in Oxfordshire and the UK, contributing £15.7 billion to the UK economy in 2018/19, and supporting over 28,000 full-time jobs .

Forward-looking statements
This release may contain forward-looking statements within the meaning of applicable securities laws, including the United States Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding strategy, business plans and direction of Olink. The words “may”, “will”, “could”, “should”, “should”, “expect”, “plan”, “anticipate”, “intend”, “believe”, ” estimates’, ‘predicts’, ‘project’, ‘potential’, ‘pursue’, ‘target’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. All forward-looking statements contained in this press release are based on management’s current expectations and beliefs as of the date hereof and are subject to a number of important risks, uncertainties and factors that may cause actual events or results differ materially from those expressed or implied. by any forward-looking statements contained in this press release, including, without limitation, those relating to Olink’s business, operations, supply chain, strategy, objectives and anticipated timelines, including including for the delivery of Olink Explore 3072 and the expansion of the Explore platform, competition and other risks identified in the section titled “Risk Factors” in Olink’s registration statement on Form F- 1, as amended (File No. 333-253818) filed with the United States Securities and Exchange Commission (SEC) and in the other filings, reports and documents that Olink files from time to time with the SEC. Olink expressly disclaims any obligation to update any forward-looking statements contained in this release to reflect any change in its expectations with respect thereto or any change in events, conditions or circumstances on which such statement is based, except as required by law or regulations require it.


Back To Top